DR REDDYS LABORATORIES LTD (RDY) Form 6-K — Oct 23, 2026
Dr. Reddy's Laboratories reported Q2 FY27 (Sept quarter) consolidated revenue of ₹86,708 Mn, down 1.5% YoY but up 7.4% QoQ, with net profit attributable to equity holders of ₹9,250 Mn — a 36% YoY decline. EBITDA was ₹17,828 Mn at 20.6% of revenues, recovering sharply from the semaglutide-impacted Q1 margin of 12.5% but well below the prior year's 26.7%. The headline weakness was driven by North America, where revenue fell 23% YoY to ₹24,890 Mn on lower lenalidomide sales, and by ongoing semaglutide API quality issues, including an August 2026 recall in Canada that cost ₹710 Mn in expected product returns on top of the earlier ₹2,397 Mn provision.
Key figures
- Eps
- ₹11.10 diluted (Q2FY27); ₹16.42 (H1FY27)
- Revenue
- ₹86,708 Mn (Q2FY27, $905Mn)
- Net Income
- ₹9,250 Mn attributable to equity holders (Q2FY27); ₹13,685 Mn (H1FY27)
- Total Debt
- ₹72,287 Mn loans and borrowings
- Revenue Yoy
- -1.5% (Q2FY27)
- Cash Position
- ₹86,670 Mn cash, equivalents and other investments as of Sep 30, 2026
- Q2 ebitda
- ₹17,828 Mn (20.6% of revenues)
- H1 revenue
- ₹167,413 Mn (-3.5% YoY per release; -4% per segment table)
- Q2 ebitda yoy
- -24%
- Annualized roce
- 9.5%
- Q2 gross margin
- 52.1%
- India q2 revenue
- ₹18,508 Mn (+17% YoY)
- Net cash surplus
- ₹25.0 Bn
- Free cash flow q2
- ₹1.7 Bn
- H1 profit after tax
- ₹13,685 Mn (-52% YoY)
- Pending usda filings
- 80 (77 ANDAs, 3 NDAs)
- North america q2 revenue
- ₹24,890 Mn (-23% YoY)
- Semaglutide api provision
- ₹2,397 Mn (Q1FY27)
- Emerging markets q2 revenue
- ₹20,595 Mn (+24% YoY)
- Semaglutide canada recall charge
- ₹710 Mn (Q2FY27)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.